PERSON
BioMarin Appoints Industry Veterans from Amgen and Roche in Executive Revamp
BioMarin, executive restructuring, Amgen, Roche, Greg Friberg, James Sabry, Roctavian, hemophilia A gene therapy
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.
BioMarin Appoints New R&D and Business Development Leaders
BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs
Neptune Medical Secures $97M in Funding, Launches Jupiter Endovascular Subsidiary
Neptune Medical, Jupiter Endovascular, GI robotics, endovascular technology, Series D financing, medical device innovation, healthcare technology
Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma
Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.
Grail Lays Off About 350 Employees, Puts Brakes on New Hires
Grail, layoffs, restructuring, biotech, cancer detection, Galleri test, Illumina, workforce reduction, cost-cutting measures
Galderma’s IL-31 Blocker Nemluvio Gains FDA Approval for Prurigo Nodularis
Galderma, Nemluvio, IL-31 blocker, FDA approval, prurigo nodularis, therapeutic dermatology
FDA Approves Sandoz and Ascendis Pharma’s Treatments for nAMD and Hypoparathyroidism
FDA approval, Sandoz, Ascendis Pharma, nAMD, hypoparathyroidism, Yorvipath, TransCon PTH
Galderma’s Nemluvio Receives FDA Approval for Prurigo Nodularis Treatment
Nemluvio, Galderma, FDA Approval, Prurigo Nodularis, IL-31 Inhibitor, Chronic Skin Condition, Itch Treatment
Ascendis Pharma Secures FDA Approval for YORVIPATH, a Novel Hormone Replacement Therapy for Hypoparathyroidism
Ascendis Pharma, YORVIPATH, FDA approval, hormone replacement therapy, hypoparathyroidism, TransCon PTH, palopegteriparatide